Decoding the Future of K-Bio Value
Navigating the Quantum Leap of K-Bio
-
K-Bio Industry Overview: 2025 Performance and 2026 Outlook In 2025, the K-Bio industry demonstrated solid growth, driven by expanding global demand for biopharmaceuticals and the strengthening competitiveness of Korean biotech companies. Exports of biopharmaceutical products increased steadily, supported by large-scale biologics manufacturing, growing biosimilar penetration, and continued progress in innovative…
-
“Beyond RNA 1.0 (Silencing) to RNA 2.0 (Replacement)” Rznomics’ core value lies in its world-first RNA Trans-splicing Ribozyme platform. While traditional RNAi technologies (like siRNA) focus on “cutting and destroying” harmful mRNA, Rznomics focuses on “reprogramming” it. 1. Core Platform: RNA Trans-splicing Ribozyme This technology utilizes a “molecular pair of…
● Latest Articles
-
Celltrion vs. Samsung Bioepis: Which One Holds the Global Edge?
For everyday investors, choosing between South Korea’s two biotech titans—Celltrion and Samsung Bioepis—often feels like choosing between a “pioneering architect” and a “master manufacturer.” As…
-
Hanmi Pharm
1. LAPSCOVERY™: The Verified Bio-Platform Hanmi’s core technical advantage is the LAPSCOVERY™ (Long-Acting Protein/Peptide Discovery) technology. LAPSCOVERYTM Long Acting Protein / Peptide Discovery Platform Technology Overview Biologics have…
-
Samsung Bioepis
The Shift from “First Mover” to “Smart Follower” and Innovation In 2026, Samsung Bioepis is executing a dual-track strategy: stabilizing its massive biosimilar engine while…
-
Celltrion
Celltrion’s strategy is built on three technological driving forces: SC Formulation (Drug Delivery), Next-Gen ADC (Precision Oncology), and Multispecific Antibodies (Immune Modulation). 1. High-Concentration SC…
● About Me
“PhD Scientist & 10-Year K-Bio Investor: Decoding the Life Science of Value.”
I am a Life Sciences PhD with industrial R&D experience across mAbs, BsAbs, ADCs, Vaccines, Cell/Gene Therapy and Medical Devices. By merging my technical expertise with over a decade of active investment in the K-Bio market, I translate complex innovation into clear, data-driven insights to help you find the real value behind the jargon.
K-Bio Value Report 